Synthroid vs Armour Thyroid: How to Switch Between Them Safely

What Synthroid (Levothyroxine) Actually Contains

Synthroid is a brand-name formulation of levothyroxine sodium, a synthetic version of the thyroid prohormone T4. Each tablet delivers a single active molecule. The body converts T4 into the metabolically active hormone T3 through peripheral deiodinase enzymes in the liver, kidneys, and other tissues.

The 2014 American Thyroid Association (ATA) guidelines recommend levothyroxine monotherapy as the standard of care for hypothyroidism, citing its long half-life (approximately 7 days), consistent potency, decades of clinical outcome data, and low cost [1]. Levothyroxine achieves steady-state serum levels within 5 to 6 weeks of a fixed dose. That pharmacokinetic stability makes monitoring straightforward: a single TSH draw 6 to 8 weeks after a dose change is usually sufficient to confirm adequacy.

Generic levothyroxine is available from multiple manufacturers. The FDA requires bioequivalence within a 90% to 111% range of the reference product for narrow-therapeutic-index drugs, but brand-to-generic and generic-to-generic switches can still produce clinically meaningful TSH shifts in sensitive patients [2]. Sticking with one manufacturer reduces that variability.

What Armour Thyroid (Desiccated Thyroid Extract) Contains

Armour Thyroid is a porcine-derived desiccated thyroid extract (DTE). Each 60 mg grain delivers approximately 38 mcg of T4 and 9 mcg of T3, along with trace amounts of T1, T2, and calcitonin [3]. The fixed T4:T3 ratio is roughly 4.2:1.

That ratio matters because the human thyroid gland secretes T4 and T3 at a ratio closer to 14:1 [4]. The relative excess of T3 in Armour means that serum T3 levels peak 2 to 4 hours after ingestion, then decline over the day. Patients may notice a brief energy surge followed by a taper. Some clinicians split the daily dose (morning and early afternoon) to blunt those peaks.

Armour Thyroid has been used since the late 1800s. Before synthetic levothyroxine became available in the 1960s, DTE was the only treatment option. Its long clinical track record is not in dispute. The debate centers on whether the added T3 component produces measurable benefits over T4 monotherapy.

Head-to-Head Evidence: What the Trials Show

No large, long-term randomized controlled trial has definitively proven one formulation superior. The best direct comparison remains the Hoang et al. 2013 crossover trial published in the Journal of Clinical Endocrinology and Metabolism [3].

In that study, 70 patients with primary hypothyroidism received 16 weeks of levothyroxine followed by 16 weeks of DTE (or the reverse). TSH levels were statistically similar between the two arms. But 49% of participants preferred DTE compared with 19% who preferred levothyroxine (P = 0.001) [3]. Patients on DTE also lost an average of 1.5 kg more than on levothyroxine, and there was a modest decrease in total cholesterol. No serious adverse events occurred in either group.

The ATA guidelines acknowledged this preference signal but stopped short of recommending DTE, noting that "the physiologic ratio of T4 to T3 in DTE is not equivalent to the human ratio" and that long-term cardiovascular safety data for combination T4/T3 products are lacking [1]. The guidelines rated the evidence as "weak" and stated: "We recommend against the routine use of combination T4 and T3 therapy... due to the absence of long-term outcome data" [1].

A 2012 European Thyroid Association (ETA) guideline review reached a similar conclusion, finding insufficient evidence to recommend combination therapy as standard practice, while noting that a subgroup of patients with persistent symptoms on T4 monotherapy may warrant a therapeutic trial of added T3 [5].

Why Patients Ask to Switch

The most common reason is persistent symptoms despite a normal TSH. Approximately 5% to 10% of levothyroxine-treated hypothyroid patients report ongoing fatigue, cognitive sluggishness, or weight gain even when TSH falls within the reference range of 0.4 to 4.0 mIU/L [6]. Several hypotheses explain this phenomenon.

Impaired T4-to-T3 conversion. Polymorphisms in the DIO2 gene (encoding type 2 deiodinase) may reduce peripheral conversion of T4 to T3. A 2009 study published in the Journal of Clinical Endocrinology and Metabolism found that patients carrying the Thr92Ala variant of DIO2 reported improved well-being on combination T4/T3 therapy compared with T4 monotherapy [7]. The clinical significance of genotyping remains debated, but this mechanism is biologically plausible.

T3 levels in the low-normal range. Some patients on levothyroxine monotherapy have serum free T3 levels in the lower quartile of the reference range. Adding exogenous T3 (whether via DTE or synthetic liothyronine) raises free T3 into the mid-range. Whether that shift produces subjective improvement independent of placebo effect is unclear from existing trials.

Placebo and expectation effects. Switching medications itself can produce perceived benefit. The Hoang trial was not blinded for the DTE arm (capsule appearance differed), which limits the strength of its preference finding [3].

The decision to switch should involve a shared conversation between patient and clinician. Checking free T4, free T3, and thyroid antibodies before the switch helps establish a baseline and rule out alternative diagnoses such as central hypothyroidism or coexisting autoimmune conditions.

How to Switch from Synthroid to Armour Thyroid

The conversion is not milligram-to-milligram. The widely cited equivalence is:

• 100 mcg levothyroxine ≈ 60 mg (1 grain) Armour Thyroid
• 50 mcg levothyroxine ≈ 30 mg (0.5 grain) Armour Thyroid
• 150 mcg levothyroxine ≈ 90 mg (1.5 grains) Armour Thyroid

These ratios are approximate. AACE/ACE 2012 guidelines note that dose equivalency tables for thyroid hormone preparations have not been validated in large prospective studies, and individual titration is required [2].

A conservative approach starts with a slightly lower equivalent dose of Armour and titrates upward based on labs at 6 to 8 weeks. For example, a patient stable on 125 mcg of levothyroxine might begin on 60 mg (1 grain) of Armour rather than the arithmetically proportional 75 mg. The added T3 compensates for the slight T4 shortfall.

Timing also changes. Armour should be taken on an empty stomach, 30 to 60 minutes before breakfast (same as levothyroxine). Some patients splitting the dose take the second portion 6 to 8 hours later. Coffee, calcium supplements, and proton pump inhibitors should remain separated by at least 4 hours, as they impair absorption of both formulations [1].

Stop the levothyroxine completely the day Armour begins. There is no need for an overlap period. T4 has a 7-day half-life, so residual levothyroxine will taper gradually over the first few weeks.

How to Switch from Armour Thyroid to Synthroid

The reverse switch uses the same conversion ratios in the opposite direction. One grain (60 mg) of Armour converts to approximately 88 to 100 mcg of levothyroxine [2]. The range reflects the fact that some of Armour's clinical effect comes from its T3 content, which has no direct levothyroxine equivalent.

Patients switching from Armour to levothyroxine may notice a temporary dip in energy during the first 2 to 3 weeks. That dip occurs because exogenous T3 clears rapidly (half-life of approximately 1 day), and the newly started levothyroxine takes 5 to 6 weeks to reach steady state. Reassurance helps. The adjustment is transient.

Check TSH and free T4 at 6 weeks. If TSH is above goal, increase levothyroxine by 12.5 to 25 mcg and recheck in another 6 weeks. If TSH is suppressed below 0.1 mIU/L, reduce the dose and monitor for atrial fibrillation risk, particularly in patients over age 60 [1].

Monitoring After the Switch

Both directions require the same monitoring cadence. Draw TSH 6 to 8 weeks after the switch. For patients now on Armour, consider adding free T3 to the lab panel, drawn mid-morning (4 to 5 hours post-dose) to capture the T3 peak rather than the trough.

Target TSH depends on the clinical context. The ATA recommends a TSH of 0.5 to 2.5 mIU/L for most adults on thyroid hormone replacement, with a slightly higher target (up to 4.0 mIU/L) acceptable in older adults to avoid subclinical hyperthyroidism [1]. In the Hoang trial, both levothyroxine and DTE arms maintained TSH within 0.5 to 3.0 mIU/L without significant difference between groups [3].

Watch for signs of overreplacement on Armour: resting heart rate above 90 bpm, tremor, heat intolerance, or insomnia. These symptoms suggest either excess T3 effect or a dose that is too high overall. A bone density check at baseline is reasonable for postmenopausal women switching to any T3-containing regimen, as chronic T3 excess accelerates bone turnover [8].

Repeat labs at 3 months, then every 6 to 12 months once the dose stabilizes. Dose requirements may shift with weight changes, pregnancy, aging, or the addition of estrogen therapy (which increases thyroxine-binding globulin and may raise levothyroxine requirements by 20% to 40%) [1].

Who Should Stay on Levothyroxine

Levothyroxine remains the right choice for the majority of hypothyroid patients. The ATA guidelines are explicit: "Levothyroxine should remain the preparation of choice for the treatment of hypothyroidism" [1]. Specific populations where levothyroxine is preferred include:

Patients with atrial fibrillation or cardiovascular disease. The T3 peaks from Armour can increase heart rate and myocardial oxygen demand. A 2015 analysis in Thyroid found that even mild TSH suppression (<0.1 mIU/L) increased atrial fibrillation risk by 1.6-fold in adults over 60 [8].

Pregnant patients. No safety data support DTE use during pregnancy. Levothyroxine is the only thyroid hormone replacement with pregnancy outcome studies. TSH targets during pregnancy are trimester-specific (0.1 to 2.5 mIU/L in the first trimester per ATA guidelines) [1].

Patients who are well-controlled and asymptomatic. If TSH is on target and the patient reports no residual symptoms, switching adds risk without expected benefit.

Patients on tight medication schedules. Levothyroxine once daily is simpler than split-dose Armour. Adherence matters. Missed doses on a twice-daily Armour regimen produce larger day-to-day fluctuations in T3.

Who May Benefit from a Trial of Armour Thyroid

A subset of patients may genuinely feel better on DTE. The Hoang trial data, while limited, showed a real preference signal with a modest weight and lipid benefit [3]. Candidates for a supervised trial include:

Patients with persistent hypothyroid symptoms (fatigue, brain fog, weight gain) despite 6 or more months of optimized levothyroxine therapy with a TSH between 0.5 and 2.0 mIU/L. Alternative causes of fatigue (iron deficiency, sleep apnea, depression) should be excluded first.

Patients with low-normal free T3 on levothyroxine monotherapy. If free T3 sits in the bottom 20% of the reference range despite adequate TSH, exogenous T3 may correct that gap.

Patients who have tried levothyroxine from multiple manufacturers and still report symptoms. Brand switching rules out excipient sensitivity and bioequivalence drift as confounders.

The trial should be time-limited: 12 to 16 weeks, matching the Hoang protocol. If the patient reports no meaningful improvement by that point and labs are comparable, switch back to levothyroxine rather than continuing indefinitely on a less-studied formulation.

Cost, Insurance, and Access

Generic levothyroxine costs $4 to $15 per month at most pharmacies. Brand-name Synthroid runs $30 to $50 with insurance, higher without. Armour Thyroid is a branded product with no AB-rated generic, so out-of-pocket costs range from $30 to $75 per month depending on dose and pharmacy.

Insurance coverage for Armour Thyroid varies by plan. Some formularies exclude DTE products or require prior authorization. If cost is a barrier, NP Thyroid and WP Thyroid are alternative DTE brands, though supply has been inconsistent due to FDA recalls related to sub-potency or super-potency findings in 2020 and 2021 [9].

Compounded T4/T3 preparations are available from specialty pharmacies and allow custom ratios, but the ATA guidelines specifically recommend against compounded thyroid hormones "due to concerns about product consistency" [1]. Patients considering this route should understand that compounded preparations lack the FDA potency testing applied to commercially manufactured tablets.

Switching Protocols: A Quick-Reference Table

| Current Medication | Approximate Equivalent | |---|---| | Levothyroxine 50 mcg | Armour 30 mg (0.5 grain) | | Levothyroxine 75 mcg | Armour 30 to 60 mg (0.5, 1 grain) | | Levothyroxine 100 mcg | Armour 60 mg (1 grain) | | Levothyroxine 125 mcg | Armour 60 to 90 mg (1, 1.5 grains) | | Levothyroxine 150 mcg | Armour 90 mg (1.5 grains) | | Levothyroxine 200 mcg | Armour 120 mg (2 grains) |

Start at or slightly below the equivalent dose and titrate based on TSH at 6 to 8 weeks. Do not adjust more frequently than every 6 weeks, as premature retesting reflects residual steady-state changes, not the new dose effect.